Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Inventory (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Inventory for 17 consecutive years, with $2.7 billion as the latest value for Q4 2025.

  • Quarterly Inventory rose 5.2% to $2.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 billion through Dec 2025, up 5.2% year-over-year, with the annual reading at $2.7 billion for FY2025, 5.2% up from the prior year.
  • Inventory for Q4 2025 was $2.7 billion at Bristol Myers Squibb, down from $2.8 billion in the prior quarter.
  • The five-year high for Inventory was $3.3 billion in Q3 2024, with the low at $2.0 billion in Q1 2021.
  • Average Inventory over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2023.
  • The sharpest move saw Inventory tumbled 31.14% in 2021, then skyrocketed 36.78% in 2024.
  • Over 5 years, Inventory stood at $2.1 billion in 2021, then rose by 11.65% to $2.3 billion in 2022, then increased by 13.81% to $2.7 billion in 2023, then dropped by 3.94% to $2.6 billion in 2024, then grew by 5.2% to $2.7 billion in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $2.7 billion, $2.8 billion, and $2.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.